ROCKET PHARMACEUTICALS, INC.

(RCKT)
  Report
Delayed Nasdaq  -  04:00 2022-07-06 pm EDT
16.15 USD   +3.99%
09:07aSVB Securities Adjusts Price Target on Rocket Pharmaceuticals to $64 From $66, Keeps Outperform Rating
MT
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQGM : RCKT) dropped from Russell 3000 Growth Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQGM : RCKT) added to Russell Microcap Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
13.03(c) 13.76(c) 14.45(c) 15.53(c) 16.15 Last
560 204 714 151 1 012 023 704 943 916 581 Volume
+1.24% +5.60% +5.01% +7.47% +3.99% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 0,13 M - -
Net income 2022 -186 M - -
Net cash position 2022 239 M - -
P/E ratio 2022 -5,81x
Yield 2022 -
Sales 2023 61,4 M - -
Net income 2023 -176 M - -
Net cash position 2023 178 M - -
P/E ratio 2023 -7,77x
Yield 2023 -
Capitalization 1 063 M 1 063 M -
EV / Sales 2022 6 590x
EV / Sales 2023 14,4x
Nbr of Employees 151
Free-Float 93,1%
More Financials
Company
Rocket Pharmaceuticals, Inc. is a clinical-stage, multi-platform biotechnology company that is focused on the development of gene therapies for rare and devastating diseases. The Company’s clinical-stage ex vivo lentiviral vector (LVV) programs include Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Danon Disease, Pyruvate Kinase Deficiency (PKD) and Infantile Malignant Osteopetrosis (IMO). FA is a... 
More about the company
Ratings of Rocket Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C-
More Ratings
All news about ROCKET PHARMACEUTICALS, INC.
09:07aSVB Securities Adjusts Price Target on Rocket Pharmaceuticals to $64 From $66, Keeps Ou..
MT
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) dropped from Russell 3000 Growth Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell Microcap Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell Microcap Value Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) dropped from Russell 2000 Growth Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) dropped from Russell 2500 Growth Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) dropped from Russell Small Cap Comp Growth In..
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell 2000 Value Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell 3000 Value Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell 3000E Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell 3000E Value Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) dropped from Russell 3000E Growth Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell 2500 Value Index
CI
06/24ROCKET PHARMACEUTICALS, INC.(NASDAQG : RCKT) added to Russell Small Cap Comp Value Index
CI
06/15ROCKET PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8..
AQ
More news
News in other languages on ROCKET PHARMACEUTICALS, INC.
05/19Rocket Pharmaceuticals présente des données de premier plan positives sur le programme ..
05/16Rocket Pharmaceuticals, Inc. présente des données cliniques positives issues des progra..
05/05Rocket Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre se termina..
04/04Rocket Pharmaceuticals nomme Fady Malik au conseil d'administration
03/11Rocket Pharmaceuticals, Inc. annonce des changements de direction
More news
Analyst Recommendations on ROCKET PHARMACEUTICALS, INC.
More recommendations
Chart ROCKET PHARMACEUTICALS, INC.
Duration : Period :
Rocket Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCKET PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 16,15 $
Average target price 57,40 $
Spread / Average Target 255%
EPS Revisions
Managers and Directors
Gaurav D. Shah Chief Executive Officer & Director
Kinnari Patel President & Chief Operating Officer
John C. Militello Treasurer, Chief Financial & Accounting Officer
Roderick T. Wong Chairman
Jonathan David Schwartz Chief Medical Officer & SVP-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
ROCKET PHARMACEUTICALS, INC.-26.02%1 022
GILEAD SCIENCES, INC.-14.14%78 194
VERTEX PHARMACEUTICALS31.59%73 908
REGENERON PHARMACEUTICALS, INC.-5.54%64 277
WUXI APPTEC CO., LTD.-4.67%49 127
BIONTECH SE-37.54%39 133